RU2596925C2 - Гуманизированные антитела, специфические для пептида-6, полученного из hsp65, способы их использования - Google Patents

Гуманизированные антитела, специфические для пептида-6, полученного из hsp65, способы их использования Download PDF

Info

Publication number
RU2596925C2
RU2596925C2 RU2012106891/10A RU2012106891A RU2596925C2 RU 2596925 C2 RU2596925 C2 RU 2596925C2 RU 2012106891/10 A RU2012106891/10 A RU 2012106891/10A RU 2012106891 A RU2012106891 A RU 2012106891A RU 2596925 C2 RU2596925 C2 RU 2596925C2
Authority
RU
Russia
Prior art keywords
ser
seq
tyr
variable region
antibody
Prior art date
Application number
RU2012106891/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012106891A (ru
Inventor
Яааков НАПАРШТЕК
Шира ЯАИР
Original Assignee
Протаб Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Протаб Лтд. filed Critical Протаб Лтд.
Publication of RU2012106891A publication Critical patent/RU2012106891A/ru
Application granted granted Critical
Publication of RU2596925C2 publication Critical patent/RU2596925C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012106891/10A 2009-09-06 2010-09-06 Гуманизированные антитела, специфические для пептида-6, полученного из hsp65, способы их использования RU2596925C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24021809P 2009-09-06 2009-09-06
US61/240,218 2009-09-06
PCT/IL2010/000731 WO2011027349A1 (en) 2009-09-06 2010-09-06 Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Publications (2)

Publication Number Publication Date
RU2012106891A RU2012106891A (ru) 2013-10-27
RU2596925C2 true RU2596925C2 (ru) 2016-09-10

Family

ID=43648941

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012106891/10A RU2596925C2 (ru) 2009-09-06 2010-09-06 Гуманизированные антитела, специфические для пептида-6, полученного из hsp65, способы их использования

Country Status (12)

Country Link
US (3) US8680241B2 (enExample)
EP (2) EP3366308A1 (enExample)
JP (1) JP5781514B2 (enExample)
KR (1) KR101831229B1 (enExample)
CN (1) CN102740877B (enExample)
AU (1) AU2010290844B2 (enExample)
BR (1) BR112012004983A2 (enExample)
CA (1) CA2772567A1 (enExample)
IN (1) IN2012DN02869A (enExample)
MX (1) MX2012002768A (enExample)
RU (1) RU2596925C2 (enExample)
WO (1) WO2011027349A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2790561C2 (ru) * 2017-09-25 2023-02-27 Адреномед Аг Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2068889T (pt) * 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
JP6829194B2 (ja) * 2014-10-24 2021-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｖｈ−ｖｌドメイン間角度に基づく抗体ヒト化の方法
WO2016116948A1 (en) 2015-01-22 2016-07-28 Ram Isanaka Peptide for treating inflammatory diseases
WO2017005923A1 (en) * 2015-07-09 2017-01-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vector expressing membrane-anchored or secreted antibody
MX385370B (es) * 2016-03-31 2025-03-18 Immutrix Therapeutics Inc Metodo para el tratamiento extracorporeo de preeclampsia y trastornos relacionados.
PL3830119T3 (pl) * 2018-08-01 2026-05-25 Imcheck Therapeutics Przeciwciała anty-btn3a i ich zastosowanie w leczeniu nowotworów albo zaburzeń zakaźnych
WO2025155809A2 (en) * 2024-01-18 2025-07-24 Nextcure, Inc. Compositions and methods for modulating vstm-1 mediated signal transduction
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050012353A1 (en) * 2001-12-31 2005-01-20 Winter Amos G Recreation vehicle
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2009064854A2 (en) * 2007-11-13 2009-05-22 Cogenesys, Inc Humanized antibodies against tl1a
RU2361877C2 (ru) * 2004-09-24 2009-07-20 Сентро Де Инженьериа Генетика И Биотекнологиа Пептиды hsp60 и их apl-производные и фармацевтические композиции

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
US7488476B2 (en) * 1998-11-05 2009-02-10 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases
DE69929454T2 (de) * 1998-11-05 2006-09-28 Hadasit Medical Research Services & Development Co. Ltd. Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
EP1619521A1 (en) 2004-07-22 2006-01-25 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Capacitive transmitter electrode
CA2596833C (en) 2005-02-03 2016-04-12 Antitope Limited Human antibodies and proteins
PT1989544E (pt) 2006-03-02 2011-09-26 Antitope Ltd Ensaios com células t
US20080019979A1 (en) * 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
RU2011143776A (ru) 2009-03-30 2013-05-10 Протаб Лтд. Белок, ассоциированный с аденилатциклазой (сар1) и применение его в качестве мишени для иммуномодуляции
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050012353A1 (en) * 2001-12-31 2005-01-20 Winter Amos G Recreation vehicle
RU2361877C2 (ru) * 2004-09-24 2009-07-20 Сентро Де Инженьериа Генетика И Биотекнологиа Пептиды hsp60 и их apl-производные и фармацевтические композиции
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2009064854A2 (en) * 2007-11-13 2009-05-22 Cogenesys, Inc Humanized antibodies against tl1a

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2790561C2 (ru) * 2017-09-25 2023-02-27 Адреномед Аг Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания

Also Published As

Publication number Publication date
KR20120060224A (ko) 2012-06-11
WO2011027349A1 (en) 2011-03-10
IN2012DN02869A (enExample) 2015-07-24
MX2012002768A (es) 2012-06-28
EP2475383A1 (en) 2012-07-18
JP2013503852A (ja) 2013-02-04
CA2772567A1 (en) 2011-03-10
EP2475383A4 (en) 2013-07-17
US20170218056A1 (en) 2017-08-03
BR112012004983A2 (pt) 2021-02-23
RU2012106891A (ru) 2013-10-27
KR101831229B1 (ko) 2018-02-22
CN102740877B (zh) 2015-01-14
EP3366308A1 (en) 2018-08-29
US8680241B2 (en) 2014-03-25
US20120156201A1 (en) 2012-06-21
US20140170138A1 (en) 2014-06-19
JP5781514B2 (ja) 2015-09-24
AU2010290844A1 (en) 2012-03-15
CN102740877A (zh) 2012-10-17
AU2010290844B2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
US20250145699A1 (en) Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor
US11512129B2 (en) TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
US20170218056A1 (en) Humanized antibodies specific for hsp65-derived peptide-6, methods and uses thereof
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
JP2014518640A (ja) β−クロトおよびＦＧＦ受容体を含む複合体に結合するヒト抗原結合タンパク質
EP3858857A1 (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
JP7753264B2 (ja) ソルチリンを認識する抗体
JP7858104B2 (ja) 抗ヒトｐ４０タンパク質ドメイン抗体及びその使用
KR20170110681A (ko) Pcsk9 항체, 및 약제학적 조성물 및 이의 용도
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途
CN120152991A (zh) 靶向人源ror1的单域抗体
HK40116870A (en) Antibodies recognizing sortilin
EA044647B1 (ru) Терапия транстиретинового (ттр) амилоидоза антителами, а также антитела, полученные от человека для указанной терапии

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200907